NGS-Guided Treatment Is Feasible for Platinum-Refractory Head and Neck Cancer
Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.
All articles by Waseem Qureshi
OSE2101 Vaccine Outperforms Standard Care in Certain Patients With NSCLC
The cancer vaccine OSE2101 improved survival in patients with HLA-A2+, advanced NSCLC and secondary resistance to ICIs in a phase 3 trial.
Radiotherapy for Prostate Cancer Linked to Higher Risk of Bladder and Lung Cancer
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
Ranitidine Does Not Increase the Risk of Cancer, Study Suggests
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Oncologists Receive More EHR Messages Than Other HCPs but Spend Less Time in EHRs
A new study suggests that electronic health records could be better tailored to meet the specific needs of oncologists.
Global Burden of Lip and Oral Cavity Cancers, Other Pharyngeal Cancers
Researchers say they have quantified the global burden of lip and oral cavity cancers as well as other pharyngeal cancers.
Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Dose-Intensive Chemoimmunotherapy “Preferred” for Untreated PMBCL
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Eliminating H2RAs From Paclitaxel Premedication Does Not Increase Infusion Reactions
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Atezolizumab Yields Durable Responses in Alveolar Soft Part Sarcoma
Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.
- Loading...
Loading...
Next post in Sarcoma
Loading... 
Loading...